Amgen Boosts Long-Term Pipeline with US$1.3 B Tularik Acquisition
By Business Review Editor
Pharma Deals Review: Vol 2004 Issue 47 (Table of Contents)
Published: 4 May-2004
DOI: 10.3833/pdr.v2004.i47.811 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Amgen entered into an agreement to acquire Tularik, substantially increasing its product portfolio in the areas of cancer, inflammatory disease, type 2 diabetes and obesity, in addition to gene expression platform focused on selectively blocking inflammatory cell signaling pathways...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS